Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and ...
Texas Facility Expansion Increases Magnet Capacity, Supports Domestic Critical-Minerals Supply Chains and Increases Post-Tax NPV to US$780 million (forecast prices) and US$409 million (current prices) ...
The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may ...
One of the reasons the Moms of the Upper East Side group so regularly winds up in the news is the presence of posts exactly ...
US FDA approves Innoviva’s Nuzolvence, a first-in-class, single-dose, oral antibiotic to treat uncomplicated urogenital gonorrhoea in adults?and adolescents: Waltham, Massachuse ...
The FDA has cleared the use of GSK’s Blujepa for the treatment of uncomplicated urogenital gonorrhea, unlocking the first new ...
FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against ...
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, ...
Igyxos Biotherapeutics is dedicated to developing innovative treatments for infertility in both men and women. Its lead asset, IGX12, is a first-in-class potentiating monoclonal antibody designed to ...
MedPage Today on MSN
Novel ITP Drug Helps Patients Ditch Daily Meds
First-in-class ianalumab in second-line setting led to sustained disease control ...
Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...
After a three-decade drought of new antibiotics to treat gonorrhea, the FDA has signed off on two first-in-class oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback